Maricann Group Inc.
CSE : MARI
CSE : MARI.CN
CNSX : MARI
OTCQB : MRRCF
FRANKFURT : 75M

Maricann Group Inc.

January 29, 2018 08:29 ET

Maricann Group Inc. Announces $70 Million Bought Deal Equity Financing

BURLINGTON, ONTARIO--(Marketwired - Jan. 29, 2018) -

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) ("Maricann" or the "Company"), is pleased to announce that it has entered into a letter of engagement with Eight Capital, under which Eight Capital has agreed to purchase, as joint bookrunner and co-lead underwriter with Canaccord Genuity Corp. ("Canaccord), and along with a syndicate of underwriters including GMP Securities L.P., Industrial Alliance Securities Inc. and Clarus Securities Inc. (together with Eight Capital and Canaccord, the "Underwriters"), 17,500,000 units of the Company (the "Units"), on a "bought deal" basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $4.00 (the "Issue Price") for gross proceeds of $70,000,000 (the "Offering").

The Company has agreed to grant Eight Capital an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional $10,500,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be $80,500,000.

Each Unit will be comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (each a "Warrant"). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $4.15, for a period of 36 months following the closing of the Offering.

The Company intends to use the net proceeds of the Offering for acquisitions, capital expenditures and for working capital and general corporate purposes.

The closing date of the Offering is scheduled to be on or about February 23, 2018 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange and the applicable securities regulatory authorities.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, capable of producing 95,000 kg of dry cannabis flower per year to support existing and future patient growth. For more information about Maricann, please visit our website at www.maricann.com.

FORWARD LOOKING INFORMATION

Certain statements in this document, including statements with respect to the proposed Offering, the use of proceeds and Closing Date and use of proceeds thereof, contain forward-looking statements which can be identified by the use of forward-looking terminology such as "believes", "expects", "may", "desires", "will", "should", "projects", "estimates", "contemplates", "anticipates", "intends", or any negative such as "does not believe" or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. Management cautions readers that the assumptions relative to the future events, several of which are beyond Management's control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Contact Information

  • Investor Relations:
    Graham Farrell
    Director of Investor Relations
    graham@maricann.com
    647-643-7665

    Corporate Headquarters (Canada)
    Maricann Group Inc. (Toronto)
    845 Harrington Court, Unit 3
    Burlington Ontario L7N 3P3
    Canada
    289-288-6274

    European Headquarters (Germany)
    Maricann GmbH
    Thierschstrasse 3, 80538 Munchen, Deutschland